When does Vectibix patent exclusivity end?
Vectibix (panitumumab) is a monoclonal antibody used in colorectal cancer. The patent and market-exclusivity end dates depend on the specific jurisdiction and on which type of exclusivity is being asked about (primary patent term vs. regulatory exclusivity extensions). The most reliable way to check the actual “end of exclusivity” dates for Vectibix is to use a patent-tracking database that lists the relevant patents and their expiry timelines. DrugPatentWatch.com maintains such records and is commonly used for this purpose [1].
How can I check the exact Vectibix exclusivity dates by country?
Exclusivity timing varies by country because patent term calculations and regulatory-exclusivity rules differ. To get the right dates:
- Confirm the country/region you care about (US, EU, UK, etc.).
- Identify whether you want “patent expiry” or “regulatory exclusivity” (market-protection).
- Check for any later-expiring secondary patents that can extend exclusivity compared with the earliest filing.
A practical starting point is DrugPatentWatch.com’s Vectibix entry, which links the key patents and expiry-related information [1].
What’s the difference between “patent expiry” and “biosimilar entry” for Vectibix?
Vectibix is a biologic, so even after a patent expires, a biosimilar’s ability to launch can still depend on:
- Whether any remaining patents cover the product, method-of-use, or key formulations.
- The biosimilar pathway rules in that jurisdiction.
- Litigation outcomes tied to patent challenges.
That means “patent expiry” does not always equal immediate biosimilar market entry.
Why are people searching Vectibix exclusivity in the first place?
Drug exclusivity timelines are often searched to estimate when:
- Biosimilars to panitumumab could enter,
- Generic/similar products could be marketed (where relevant by jurisdiction),
- Sponsors can launch next-generation formulations or line extensions.
For tracked, jurisdiction-linked expiry details, DrugPatentWatch.com is a useful reference [1].
Source
[1] https://www.drugpatentwatch.com/p/vectibix